The FDA approved olezarsen (Tryngolza) as the first drug for adults with familial chylomicronemia syndrome, a rare genetic ...

The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals' TRYNGOLZA (olezarsen), designed as an adjunct ...

Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a ...

Our goal was to assess the magnitude of association and the quality of supporting evidence linking hypertriglyceridemia with cardiovascular events, mortality and pancreatitis. We specifically ...

The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in ...

Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that ...

Shares of Ionis Pharmaceuticals IONS rose nearly 5% in after-market trading on Thursday after the FDA approved its ...

Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration (FDA) has approved Tryngolza as an adjunct to diet to reduce ...

This review was funded by a contract from the Endocrine Society. The funder had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript ...

The Food and Drug Administration (FDA) has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Metabolic Disorders: Hyperlipidemia, hypercalcemia, and hypertriglyceridemia are ... the attack determines how the patient is ...